- Home
- SNAL vs DRRX Comparison
SNAL vs DRRX Comparison
Compare SNAL & DRRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNAL
- DRRX
- Stock Information
- Founded
- SNAL 2000
- DRRX 1998
- Country
- SNAL United States
- DRRX United States
- Employees
- SNAL N/A
- DRRX N/A
- Industry
- SNAL Computer Software: Prepackaged Software
- DRRX Biotechnology: Pharmaceutical Preparations
- Sector
- SNAL Technology
- DRRX Health Care
- Exchange
- SNAL Nasdaq
- DRRX Nasdaq
- Market Cap
- SNAL 43.8M
- DRRX 44.4M
- IPO Year
- SNAL 2022
- DRRX 2000
- Fundamental
- Price
- SNAL $1.50
- DRRX $0.95
- Analyst Decision
- SNAL
- DRRX Buy
- Analyst Count
- SNAL 0
- DRRX 2
- Target Price
- SNAL N/A
- DRRX $5.00
- AVG Volume (30 Days)
- SNAL 290.2K
- DRRX 135.6K
- Earning Date
- SNAL 11-13-2024
- DRRX 11-13-2024
- Dividend Yield
- SNAL N/A
- DRRX N/A
- EPS Growth
- SNAL N/A
- DRRX N/A
- EPS
- SNAL 0.08
- DRRX N/A
- Revenue
- SNAL $86,822,973.00
- DRRX $8,594,000.00
- Revenue This Year
- SNAL $48.59
- DRRX $54.32
- Revenue Next Year
- SNAL $18.35
- DRRX N/A
- P/E Ratio
- SNAL $19.84
- DRRX N/A
- Revenue Growth
- SNAL 82.23
- DRRX N/A
- 52 Week Low
- SNAL $0.52
- DRRX $0.50
- 52 Week High
- SNAL $2.29
- DRRX $1.88
- Technical
- Relative Strength Index (RSI)
- SNAL 52.74
- DRRX 51.06
- Support Level
- SNAL $1.28
- DRRX $0.79
- Resistance Level
- SNAL $2.00
- DRRX $0.83
- Average True Range (ATR)
- SNAL 0.30
- DRRX 0.09
- MACD
- SNAL 0.03
- DRRX 0.03
- Stochastic Oscillator
- SNAL 38.97
- DRRX 76.16
About SNAL Snail Inc.
Snail Inc is a global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.
About DRRX DURECT Corporation
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .